{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:17:03Z","timestamp":1793395023134,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,2,18]]},"DOI":"10.1038\/s41388-024-03220-z","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T04:51:19Z","timestamp":1731300679000},"page":"307-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1"],"prefix":"10.1038","volume":"44","author":[{"given":"Hongxiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3150-5119","authenticated-orcid":false,"given":"Yin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-594X","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8232-8146","authenticated-orcid":false,"given":"Xinghua","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8684-6485","authenticated-orcid":false,"given":"Guodong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"3220_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3220_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","volume":"19","author":"LA Byers","year":"2013","unstructured":"Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19:279\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1558.","journal-title":"Clin Cancer Res"},{"key":"3220_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3322\/caac.21555","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69:211\u201333. https:\/\/doi.org\/10.3322\/caac.21555.","journal-title":"CA Cancer J Clin"},{"key":"3220_CR4","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71:3971\u20135. https:\/\/doi.org\/10.1073\/pnas.71.10.3971.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3220_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21:14. https:\/\/doi.org\/10.1186\/s12943-022-01500-4.","journal-title":"Mol Cancer"},{"key":"3220_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.trsl.2023.04.005","volume":"259","author":"X An","year":"2023","unstructured":"An X, Wu W, Yang L, Dong J, Liu B, Guo J, et al. ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. Transl Res. 2023;259:62\u201371. https:\/\/doi.org\/10.1016\/j.trsl.2023.04.005.","journal-title":"Transl Res"},{"key":"3220_CR7","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1093\/nar\/gkaa048","volume":"48","author":"T Liu","year":"2020","unstructured":"Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816\u201331. https:\/\/doi.org\/10.1093\/nar\/gkaa048.","journal-title":"Nucleic Acids Res"},{"key":"3220_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:110. https:\/\/doi.org\/10.1186\/s12943-019-1036-9.","journal-title":"Mol Cancer"},{"key":"3220_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7150\/ijbs.76798","volume":"19","author":"J Shi","year":"2023","unstructured":"Shi J, Zhang Q, Yin X, Ye J, Gao S, Chen C, et al. Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner. Int J Biol Sci. 2023;19:449\u201364. https:\/\/doi.org\/10.7150\/ijbs.76798.","journal-title":"Int J Biol Sci"},{"key":"3220_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188609","volume":"1876","author":"H Zhou","year":"2021","unstructured":"Zhou H, Yin K, Zhang Y, Tian J, Wang S. The RNA m6A writer METTL14 in cancers: Roles, structures, and applications. Biochim Biophys Acta Rev Cancer. 2021;1876:188609. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188609.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3220_CR11","doi-asserted-by":"publisher","first-page":"36935","DOI":"10.1074\/jbc.M501725200","volume":"280","author":"E Hiriart","year":"2005","unstructured":"Hiriart E, Gruffat H, Buisson M, Mikaelian I, Keppler S, Meresse P, et al. Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J Biol Chem. 2005;280:36935\u201345. https:\/\/doi.org\/10.1074\/jbc.M501725200.","journal-title":"J Biol Chem"},{"key":"3220_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13046-021-01871-4","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, et al. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 2021;40:80. https:\/\/doi.org\/10.1186\/s13046-021-01871-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"3220_CR13","doi-asserted-by":"publisher","unstructured":"Dong H, Zhang H, Mao X, Liu S, Xu W, Zhang Y. RBM15 promates the proliferation, migration and invasion of pancreatic cancer cell lines. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15041084.","DOI":"10.3390\/cancers15041084"},{"key":"3220_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/tox.23741","volume":"38","author":"J Feng","year":"2023","unstructured":"Feng J, Li Y, He F, Zhang F. RBM15 silencing promotes ferroptosis by regulating the TGF-beta\/Smad2 pathway in lung cancer. Environ Toxicol. 2023;38:950\u201361. https:\/\/doi.org\/10.1002\/tox.23741.","journal-title":"Environ Toxicol"},{"key":"3220_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339\u201346. https:\/\/doi.org\/10.1093\/jnci\/dji055.","journal-title":"J Natl Cancer Inst"},{"key":"3220_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"3220_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X.","journal-title":"Lancet Oncol"},{"key":"3220_CR18","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702\u201311. https:\/\/doi.org\/10.1038\/onc.2008.109.","journal-title":"Oncogene"},{"key":"3220_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169\u201381. https:\/\/doi.org\/10.1038\/nrc2088.","journal-title":"Nat Rev Cancer"},{"key":"3220_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.23.02417","volume":"42","author":"AJ Piper Vallillo","year":"2024","unstructured":"Piper Vallillo AJ, Viray H, Feldman J, Rangachari D. Management of treatment resistance in patients with advanced epidermal growth factor receptor-mutated lung cancer: personalization, parsimony, and partnership. J Clin Oncol. 2024;42:1215\u201321. https:\/\/doi.org\/10.1200\/JCO.23.02417.","journal-title":"J Clin Oncol"},{"key":"3220_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337. https:\/\/doi.org\/10.1038\/s41416-019-0573-8.","journal-title":"Br J Cancer"},{"key":"3220_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132. https:\/\/doi.org\/10.1038\/nm.3854.","journal-title":"Nat Med"},{"key":"3220_CR23","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, et al. Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36:3101\u20139. https:\/\/doi.org\/10.1200\/JCO.2018.77.7326.","journal-title":"J Clin Oncol"},{"key":"3220_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109489","volume":"231","author":"X Zhu","year":"2023","unstructured":"Zhu X, Zhou C, Zhao S, Zheng Z. Role of m6A methylation in retinal diseases. Exp Eye Res. 2023;231:109489. https:\/\/doi.org\/10.1016\/j.exer.2023.109489.","journal-title":"Exp Eye Res"},{"key":"3220_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s13402-023-00771-3","volume":"46","author":"Y Li","year":"2023","unstructured":"Li Y, Gao X, Ni C, Zhao B, Cheng X. The application of patient-derived organoid in the research of lung cancer. Cell Oncol. 2023;46:503\u201319. https:\/\/doi.org\/10.1007\/s13402-023-00771-3.","journal-title":"Cell Oncol"},{"key":"3220_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102664","volume":"122","author":"F Ciardiello","year":"2024","unstructured":"Ciardiello F, Hirsch FR, Pirker R, Felip E, Valencia C, Smit EF. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. Cancer Treat Rev. 2024;122:102664. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102664.","journal-title":"Cancer Treat Rev"},{"key":"3220_CR27","doi-asserted-by":"publisher","unstructured":"Roper N, Brown AL, Wei JS, Pack S, Trindade C, Kim C, et al. Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100007.","DOI":"10.1016\/j.xcrm.2020.100007"},{"key":"3220_CR28","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22. https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"key":"3220_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173. https:\/\/doi.org\/10.1186\/s13045-022-01391-4.","journal-title":"J Hematol Oncol"},{"key":"3220_CR30","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-20-2435","volume":"81","author":"X Zhang","year":"2021","unstructured":"Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, et al. Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res. 2021;81:3051\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2435.","journal-title":"Cancer Res"},{"key":"3220_CR31","doi-asserted-by":"publisher","unstructured":"Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12. https:\/\/doi.org\/10.1126\/scitranslmed.aaz4589.","DOI":"10.1126\/scitranslmed.aaz4589"},{"key":"3220_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01293-4","volume":"19","author":"S Wen","year":"2020","unstructured":"Wen S, Wei Y, Zen C, Xiong W, Niu Y, Zhao Y. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Mol Cancer. 2020;19:171. https:\/\/doi.org\/10.1186\/s12943-020-01293-4.","journal-title":"Mol Cancer"},{"key":"3220_CR33","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","volume":"20","author":"S Zaccara","year":"2019","unstructured":"Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608\u201324. https:\/\/doi.org\/10.1038\/s41580-019-0168-5.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3220_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320. https:\/\/doi.org\/10.1038\/nature12730.","journal-title":"Nature"},{"key":"3220_CR35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-020-00444-9","volume":"6","author":"P Song","year":"2021","unstructured":"Song P, Yang F, Jin H, Wang X. The regulation of protein translation and its implications for cancer. Signal Transduct Target Ther. 2021;6:68. https:\/\/doi.org\/10.1038\/s41392-020-00444-9.","journal-title":"Signal Transduct Target Ther"},{"key":"3220_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature14281","volume":"519","author":"CR Alarcon","year":"2015","unstructured":"Alarcon CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519:482\u20135. https:\/\/doi.org\/10.1038\/nature14281.","journal-title":"Nature"},{"key":"3220_CR37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.004.","journal-title":"Cancer Cell"},{"key":"3220_CR38","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature19342","volume":"537","author":"DP Patil","year":"2016","unstructured":"Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537:369\u201373. https:\/\/doi.org\/10.1038\/nature19342.","journal-title":"Nature"},{"key":"3220_CR39","doi-asserted-by":"publisher","DOI":"10.34133\/research.0252","volume":"6","author":"H Wang","year":"2023","unstructured":"Wang H, Liu J, Zhu X, Yang B, He Z, Yao X. AZGP1P2\/UBA1\/RBM15 cascade mediates the fate determinations of prostate cancer stem cells and promotes therapeutic effect of docetaxel in castration-resistant prostate cancer via TPM1 m6A modification. Research. 2023;6:0252. https:\/\/doi.org\/10.34133\/research.0252.","journal-title":"Research"},{"key":"3220_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13344","volume":"56","author":"F Yang","year":"2023","unstructured":"Yang F, Liu Y, Xiao J, Li B, Chen Y, Hu A, et al. Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15. Cell Prolif. 2023;56:e13344. https:\/\/doi.org\/10.1111\/cpr.13344.","journal-title":"Cell Prolif"},{"key":"3220_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102018","volume":"46","author":"M Ma","year":"2024","unstructured":"Ma M, Wang W, Li L, Wang X, Huang Q, Zhou C, et al. RBM15 facilities lung adenocarcinoma cell progression by regulating RASSF8 stability through N6 Methyladenosine modification. Transl Oncol. 2024;46:102018. https:\/\/doi.org\/10.1016\/j.tranon.2024.102018.","journal-title":"Transl Oncol"},{"key":"3220_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(16)30033-X.","journal-title":"Lancet Oncol"},{"key":"3220_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38. https:\/\/doi.org\/10.1186\/s12943-018-0777-1.","journal-title":"Mol Cancer"},{"key":"3220_CR44","doi-asserted-by":"publisher","first-page":"12566","DOI":"10.1002\/jcb.28523","volume":"120","author":"Y Gao","year":"2019","unstructured":"Gao Y, Yu M, Ma M, Zhuang Y, Qiu X, Zhao Q, et al. SPOCK1 contributes to the third-generation EGFR tyrosine kinase inhibitors resistance in lung cancer. J Cell Biochem. 2019;120:12566\u201373. https:\/\/doi.org\/10.1002\/jcb.28523.","journal-title":"J Cell Biochem"},{"key":"3220_CR45","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s11864-022-01022-7","volume":"23","author":"N Girard","year":"2022","unstructured":"Girard N. New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer. Curr Treat Options Oncol. 2022;23:1626\u201344. https:\/\/doi.org\/10.1007\/s11864-022-01022-7.","journal-title":"Curr Treat Options Oncol"},{"key":"3220_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12:63. https:\/\/doi.org\/10.1186\/s13045-019-0759-9.","journal-title":"J Hematol Oncol"},{"key":"3220_CR47","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fonc.2019.01044","volume":"9","author":"X Zhu","year":"2019","unstructured":"Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044. https:\/\/doi.org\/10.3389\/fonc.2019.01044.","journal-title":"Front Oncol"},{"key":"3220_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C, Sorensen BS, Nielsen AL. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5:172\u201382. https:\/\/doi.org\/10.21037\/tlcr.2016.04.07.","journal-title":"Transl Lung Cancer Res"},{"key":"3220_CR49","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003.","journal-title":"Sci Transl Med"},{"key":"3220_CR50","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13402-021-00652-7","volume":"45","author":"X Cui","year":"2022","unstructured":"Cui X, Wang Y, Lan W, Wang S, Cui Y, Zhang X, et al. SPOCK1 promotes metastasis in pancreatic cancer via NF-kappaB-dependent epithelial-mesenchymal transition by interacting with IkappaB-alpha. Cell Oncol. 2022;45:69\u201384. https:\/\/doi.org\/10.1007\/s13402-021-00652-7.","journal-title":"Cell Oncol"},{"key":"3220_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-019-1247-3","volume":"38","author":"MH Chien","year":"2019","unstructured":"Chien MH, Lin YW, Wen YC, Yang YC, Hsiao M, Chang JL, et al. Targeting the SPOCK1-snail\/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. J Exp Clin Cancer Res. 2019;38:246. https:\/\/doi.org\/10.1186\/s13046-019-1247-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"3220_CR52","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/s41388-024-03011-6","volume":"43","author":"M Chen","year":"2024","unstructured":"Chen M, Zou C, Tian Y, Li W, Li Y, Zhang D. An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer. Oncogene. 2024;43:1594\u2013607. https:\/\/doi.org\/10.1038\/s41388-024-03011-6.","journal-title":"Oncogene"},{"key":"3220_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13532-4","volume":"10","author":"Q Li","year":"2019","unstructured":"Li Q, Liu B, Chao HP, Ji Y, Lu Y, Mehmood R, et al. LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer. Nat Commun. 2019;10:5494. https:\/\/doi.org\/10.1038\/s41467-019-13532-4.","journal-title":"Nat Commun"},{"key":"3220_CR54","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2023.01.007","volume":"41","author":"MB Nilsson","year":"2023","unstructured":"Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41:340\u2013355.e346. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.007.","journal-title":"Cancer Cell"},{"key":"3220_CR55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hutter JC, et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021;596:576\u201382. https:\/\/doi.org\/10.1038\/s41586-021-03796-6.","journal-title":"Nature"},{"key":"3220_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22:262\u20139. https:\/\/doi.org\/10.1038\/nm.4040.","journal-title":"Nat Med"},{"key":"3220_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2:377\u201391. https:\/\/doi.org\/10.1038\/s43018-021-00195-8.","journal-title":"Nat Cancer"},{"key":"3220_CR58","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-15-0377","volume":"75","author":"M Soucheray","year":"2015","unstructured":"Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, Becker JH, et al. Intratumoral heterogeneity in EGFR-mutant NSCLC results in divergent resistance mechanisms in response to EGFR tyrosine kinase inhibition. Cancer Res. 2015;75:4372\u201383. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0377.","journal-title":"Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03220-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:33:43Z","timestamp":1738139623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03220-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,2,18]]}},"alternative-id":["3220"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03220-z","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}